Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

OCTREOTIDE

All injection strengths: general benefit

Other products in the same Health Canada class (H01CB) — coverage varies; not interchangeable

  • Lanreotide (Somatuline Autogel): general benefit

Sandostatin · DIN 02049392 · 200mcg/mL · injection solution - 5mL vial

General benefit; Health Canada lists this DIN as Cancelled post market since 2022-05-25 — choose a marketed DIN from the same-category list.Discontinued 2022-05-25 · checked 2026-09-19
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2022-05-25 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2022-05-25 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Sandostatin · DIN 02049392 Manufacturer: Novartis Pharma Canada Inc.; listing date 2007-01-02 Health Canada: Cancelled post market since 2022-05-25 · brand SANDOSTATIN · ATC H01CB02 OCTREOTIDE · form Solution · route Intravenous, Subcutaneous · ingredients OCTREOTIDE (OCTREOTIDE ACETATE) 200 MCG/ML · company Novartis pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $48.5150 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19627 · Verify on the e-Formulary ↗ (DIN 02049392)

Source record
DIN 02049392: Sandostatin Raw flags: sec3=Y Item: 920000225; group id 941; item number 2244; lccId None; manufacturer id NOV Source form: Inj Sol - 5mL Vial Pk; strength: 200mcg/mL Recorded listing: General benefit Source prices (unrounded): $97.0300; ministry $48.5150 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02049392 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19627
Interchangeable products
Octreotide Acetate Omega · DIN 02248642 · $48.5150 Octreotide Injection · DIN 02560283 · $48.5150
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 2022-05-25 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

LANREOTIDE ACETATE

· 6 products · General benefit · strengths: 60mg/Syr, 90mg/Syr, 120mg/Syr · ER Pref Syr Pk

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab

CYCLOSPORINE

· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L

GLUCAGON RDNA ORIGIN

· 2 products · General benefit · strengths: 1mg/Vial · Inj Pd-Syr Pk, Inj Pd-Vial Pk

LEFLUNOMIDE

· 16 products · General benefit · strengths: 10mg, 20mg · Tab

LEVODOPA & BENSERAZIDE

· 3 products · General benefit · strengths: 50mg & 12.5mg, 100mg & 25mg, 200mg & 50mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 92:00 and 75 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications SANDOSTATIN® (octreotide Injection) is indicated for: • The control of symptoms in patients with metastatic carcinoid and vasoactive intestinal peptide- secreting tumours (VIPomas) as well as in patients with acromegaly. Data are insufficient to determine whether SANDOSTATIN decreases the size, rate of growth, or development of metastases in patients with these tumours. • The prevention of complications following pancreatic surgery in patients undergoing high-risk procedures. • The emergency management of bleeding gastro-oesophageal varices in patients with cirrhosis and as protection from re-bleeding. SANDOSTATIN is used in association with specific intervention such as endoscopic sclerotherapy. Carcinoid Tumours SANDOSTATIN is indicated for the symptomatic treatment of metastatic carcinoid tumours where it suppresses or inhibits the severe diarrhoea and flushing episodes associated with the disease. Vasoactive Intestinal Peptide Tumours (VIPomas) SANDOSTATIN is indicated for the treatment of the profuse watery diarrhoea associated with VIP- secreting tumours. Significant improvement has been noted in the overall condition of these othe… https://pdf.hres.ca/dpd_pm/00083516.PDF PM date: 2026-02-16 Source product: SANDOSTATIN; DIN 00839191; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.